Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 1-year average of 20.00%, near the low end of its 1-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 20.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
20.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.47B
Gross Margin
0.00%
TTM Avg
20.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$1.50B
Gross Margin
57.87%
TTM Avg
56.73%
3Y Avg
61.85%
5Y Avg
-49.66%
Market Cap
$1.49B
Gross Margin
33.71%
TTM Avg
32.28%
3Y Avg
31.46%
5Y Avg
31.45%
Market Cap
$1.46B
Gross Margin
17.33%
TTM Avg
13.16%
3Y Avg
12.65%
5Y Avg
13.31%
Market Cap
$1.44B
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
Market Cap
$1.44B
Gross Margin
83.12%
TTM Avg
85.05%
3Y Avg
87.98%
5Y Avg
90.85%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.47B | 0.00% | 20.00% | 0.00% | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | 0.00% | 0.00% | 0.00% | 0.00% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 57.87% | 56.73% | 61.85% | -49.66% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 33.71% | 32.28% | 31.46% | 31.45% |
| Certara, Inc. (CERT)vs › | $1.46B | 58.33% | 60.70% | 60.53% | 60.29% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 17.33% | 13.16% | 12.65% | 13.31% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | 0.00% | 50.00% | 25.00% | 25.00% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | 83.12% | 85.05% | 87.98% | 90.85% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | 100.00% | 100.00% | 100.00% | 66.67% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
